Stockscreener 앱 받기
11.73
2.18%
-0.19
전일 마감가:
$11.92
열려 있는:
$11.61
하루 거래량:
63,289
Relative Volume:
0.34
시가총액:
$416.25M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+17.19%
1개월 성능:
+51.23%
6개월 성능:
-44.24%
1년 성능:
+0.00%
1일 변동 폭
$11.30
$12.05
1주일 범위
$9.805
$12.40
52주 변동 폭
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
명칭
Zenas Biopharma Inc
전화
857-271-2954
주소
852 WINTER STREET, SUITE 250, WALTHAM
ZBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
11.67 | 416.25M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.81 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.12 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.55 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.34 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.97 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Wedbush | Outperform |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming DeadlinesZBIO - TradingView
Bullish Zenas BioPharma Insiders Loaded Up On US$2.11m Of Stock - simplywall.st
The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - StreetInsider
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your RightsZBIO - PR Newswire
Cohen Milstein Seeks Investors to Lead Suit to Hold Zenas BioPharma (ZBIO) Accountable for IPO-Related Fraud - GlobeNewswire
The Gross Law Firm Reminds Zenas BioPharma, Inc. Investors - GlobeNewswire
The Gross Law Firm Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 – ZBIO - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - StreetInsider
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contact the Law Firm for Information - Bluefield Daily Telegraph
Robbins LLP Reminds ZBIO Stockholders with Large Losses to - GlobeNewswire
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contact the Law Firm for Information on Leading the Zenas BioPharma, Inc. Class Action - TradingView
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm - PR Newswire
ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
ZBIO Investor Reminder: Cohen Milstein Encourages Zenas - GlobeNewswire
Zenas BioPharma, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before June 16, 2025 to Discuss Your RightsZBIO - Morningstar
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, - GlobeNewswire
The Gross Law Firm Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and ... - Bluefield Daily Telegraph
Zenas Biopharma director Xiao Ting buys $77,600 in stock - Investing.com
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - marketscreener.com
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 16, 2025 to Discuss Your RightsZBIO - PR Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - GlobeNewswire
Zenas BioPharma Investors Encouraged to Contact Cohen - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas - Bluefield Daily Telegraph
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zenas - GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc.(ZBIO) Shareholders - marketscreener.com
Zenas Biopharma (ZBIO) vs. Its Peers Head to Head Review - Defense World
Cohen Milstein Seeks Investors Willing to Lead Zenas BioPharma (ZBIO) Securities Fraud Class Action - GlobeNewswire
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas - GlobeNewswire
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Zenas BioPharma, Inc. (NASDAQ - Bluefield Daily Telegraph
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Zenas BioPharma, Inc. (NASDAQ: ZBIO); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel - GlobeNewswire
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed - GlobeNewswire
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class - Bluefield Daily Telegraph
The Gross Law Firm Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineZBIO - PR Newswire
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ZBIO LAWSUIT ALERT: The Gross Law Firm Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TradingView
ZBIO LAWSUIT ALERT: The Gross Law Firm Notifies Zenas BioPharma, Inc. Investors of a Class - Bluefield Daily Telegraph
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - Morningstar
Zenas BioPharma Insiders US$407k Short Of Breakeven On Stock Purchase - Yahoo Finance
Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses - GlobeNewswire
ZBIO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Lawsuit filed for Investors who lost money with shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) - openPR.com
ROSEN, A LONGSTANDING LAW FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
Zenas Biopharma Inc (ZBIO) 재무 분석
Zenas Biopharma Inc (ZBIO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Zenas Biopharma Inc 주식 (ZBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
0.08%
0.47%
자본화:
|
볼륨(24시간):